Skip to main content

Table 2 Primary and Secondary outcomes

From: Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial

 

Oral sildenafil

IV sildenafil

P value

Time (Hours) taken for pulmonary pressures to reduce below 25 mm Hg

Median [IQR]

48 (24—96)

(N = 17)

48 (36 – 60)

(N = 15)

0.302

Time for OI to decrease by 25% (hours)

Median [IQR]

12 (9–24)

N = 9

24 (6–37.50)

N = 14

0.281

Days on invasive ventilation

Median [IQR]

4 (2–7.5)

N = 8a

2.5 (2–3.75)

N = 17b

0.963

Days on non-invasive ventilation

Median [IQR]

5 (2–6.75)

N = 20

6 (4.25–8.75)

N = 20

0.831

Days on nasal oxygen

Median [IQR]

2.50 (0–6)

N = 13

0 (0–3)

N = 9

0.530

Duration of hospital stay (Days)

Median [IQR]

11.5 (8.75–21.50) 

N = 18

19 (12–25)

N = 19

0.151

Outcome

  

 > 0.99

 Mortality

0

0

 

 Discharge

18

19

 

Failure of treatment

8

9

 > 0.99

Complications

  

0.049

 Hypotension

0

4

 

 Poor cardiac contractility

0

1

 

Reached full feeds on

(DOL)

Median [IQR]

5 (4–6.50)

N = 13

4 (3–6.25)

N = 18

0.361

  1. DOL day of life, OI oxygenation index, IQR interquartile range
  2. aThree out of 8 neonates in oral group required HFOV ventilation
  3. bSix out of 17 neonates in IV group required HFOV ventilation